Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Dulaney

Gastroenterology Jbsa Ft Sam Houston, TX Medical Doctor

NPI 1427443456 CMS profile 2776792

3551 Roger Brooke Dr, Jbsa Ft Sam Houston, TX 78234

Open in the dashboard

General payments

$116,712

168 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$27,967 paid to institutions, not to them · program year 2025

Through program year 2025, David Dulaney of Jbsa Ft Sam Houston, TX is reported in the CMS Open Payments database as having received $116,712 across 168 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $27,967 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $84,735 73
2024 General $29,613 64
2023 General $878 11
2022 General $344 6
2021 General $377 7
2020 General $142 1
2019 General $623 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Dulaney
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to David Dulaney were reported at $84,735. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year David Dulaney Gastroenterology median Middle half National median
2019 $623 $417 $126–$1,100 $163
2020 $142 $224 $74–$624 $114
2021 $377 $352 $106–$1,054 $132
2022 $344 $448 $129–$1,270 $149
2023 $878 $533 $150–$1,390 $160
2024 $29,613 $605 $160–$1,606 $164
2025 $84,735 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $33,929 38 payments
  2. Regeneron Healthcare Solutions, Inc. $28,943 35 payments
  3. Genzyme Corporation $25,956 19 payments
  4. Lilly USA, LLC $25,098 38 payments
  5. Celgene Corporation $859 11 payments
  6. AbbVie, Inc. $802 11 payments
  7. Intercept Pharmaceuticals, Inc. $238 2 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $184 2 payments
  9. Medtronic, Inc. $148 1 payment
  10. Phathom Pharmaceuticals, Inc. $131 2 payments
  11. Other $424 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $95,589 22 payments
  2. Travel and Lodging $15,440 59 payments
  3. Food and Beverage $5,669 86 payments
  4. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. ENTYVIO $33,020 33 payments
  2. DUPIXENT Immunology $25,927 18 payments
  3. OMVOH $22,474 21 payments
  4. DUPIXENT Inflammation And Immunology $10,082 17 payments
  5. DUPIXENT Immunology And Inflammation $9,070 13 payments
  6. ZEPOSIA $859 11 payments
  7. MAVYRET $242 2 payments
  8. HUMIRA $209 2 payments
  9. XIFAXAN $184 2 payments
  10. EndoFlip $148 1 payment
  11. Other $1,097 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

168 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record